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Background:  Cheyne-Stokes  respiration  (CSR-CSA)  is often  observed  in  patients  with  chronic  heart  failure
(CHF).  Although  cardiac  resynchronization  therapy  (CRT)  is  effective  for CHF  patients  with left  ventricular
dyssynchrony,  it  is  still  unclear  whether  adaptive  servo  ventilation  (ASV)  improves  cardiac  function  and
prognosis  of  CHF  patients  with  CSR-CSA  after  CRT.
Methods  and  results:  Twenty  two  patients  with  CHF  and  CSR-CSA  after  CRT deﬁbrillator  (CRTD)  implan-
tation  were  enrolled  in  the  present  study  and  randomly  assigned  into  two groups:  11 patients  treated
with  ASV  (ASV  group)  and  11 patients  treated  without  ASV  (non-ASV  group).  Measurement  of  plasma
B-type  natriuretic  peptide  (BNP)  levels  (before  3, and  6  months  later)  and  echocardiography  (before  and
6 months)  were  performed  in  each  group.  Patients  were  followed  up  to register  cardiac  events (cardiacbesity
entilation
rain natriuretic peptides
utcomes assessment
death  and  re-hospitalization)  after  discharge.  In the ASV  group,  indices  for  apnea-hypopnea,  central  apnea,
and oxyhemoglobin  saturation  were  improved  on  ASV.  BNP  levels,  cardiac  systolic  and  diastolic  function
were  improved  with  ASV  treatment  for 6  months.  Importantly,  the  event-free  rate  was  signiﬁcantly  higher
in the  ASV  group  than  in  the non-ASV  group.
Conclusions:  ASV  improves  CSR-CSA,  cardiac  function,  and  prognosis  in  CHF  patients  with  CRTD.  Patients
with  CSR-CSA  and  post  CRTD  implantation  would  get beneﬁts  by treatment  with  ASV.
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Chronic heart failure (CHF) is a major cause of death of
he elderly in developed countries. A number of randomized
arge-scale clinical trials have demonstrated optimal medical
anagement including angiotensin-converting enzyme (ACE)
nhibitors, -blockers, aldosterone antagonists, etc. improve clin-
cal symptoms, cardiac function, and event-free survival in CHF
1–3]. However, CHF is still associated with a high rate of mor-
ality. Identiﬁcation of factors contributing to high mortality may
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ead to the development of a new strategy to treat CHF. Sleep-
isordered breathing is often observed in patients with CHF [4].  The
resence of sleep-disordered breathing, either obstructive sleep
pnea or Cheyne-Stokes respiration with central sleep apnea (CSR-
SA), has adverse prognostic impacts in CHF [5–7]. The respiratory
enter’s instability is thought to be the major cause of CSR-CSA,
nd adaptive servo ventilation (ASV) is a ventilator support system
peciﬁcally designed to normalize ventilation in patients with CSR-
SA [5–8]. ASV can regulate the airway ventilation volume upon
emand based on the variable tidal volume throughout the period
f CSR [5–8]. In addition, ASV automatically provides positive pres-
ure ventilation during apnea, when necessary.Cardiac resynchronization therapy (CRT) with biventricular
acing is an effective adjunctive therapy to pharmacological man-
gement in CHF. CRT improves functional status, exercise capacity,
uality of life, and mortality in CHF patients with left ventricular
vier Ltd. All rights reserved.
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ystolic dysfunction and intra-ventricular conduction delay [5–7].
lthough sustained effective therapy for CHF including optimal
harmacotherapy and CRT has been shown to reduce the severity
f CSR-CSA, CSR-CSA is frequently observed in CHF patients with
RT [5–7]. In addition, the effect of ASV on CSR-CSA remained after
RT implantation has not been previously studied.
Therefore, we examined whether ASV improved CSR-CSA, car-
iac function, and prognosis in CHF patients with CRT.
ethods
ubjects and study protocol
In the present study, 22 patients with CHF and CSR-CSA
ho had implanted CRT with deﬁbrillator (CRTD) were enrolled.
t 12 months after CRTD implantation, polysomnography was
erformed. The inclusion criteria were (1) the presence of symp-
omatic HF, which was deﬁned as New York Heart Association
NYHA) class II or greater, (2) standard pharmacotherapy (including
CE inhibitors, angiotensin II receptor blockers, -blockers, aldos-
erone antagonists, and diuretics) based on a guideline, (3) stable
linical status, which was deﬁned as receiving optimal medical
herapy and without worsening of CHF for at least 6 months prior
o study enrollment, and (4) diagnosed as having moderate-severe
SR-CSA, which was deﬁned as apnea-hypopnea index (AHI) > 15
5–7]. The exclusion criteria were (1) age < 20 or >80 years, (2)
evere valvular heart disease, (3) the presence of severe chronic
ulmonary disease, (4) on dialysis, and (5) history of stroke with
eurological deﬁcit [5–7]. The patients were randomly assigned
nto 2 groups by lot method: 11 patients treated with ASV (ASV
roup) and 11 patients treated without ASV (non-ASV group).
ritten informed consent was obtained from all study subjects.
he study protocol was  approved by the ethical committee of
ukushima Medical University.
Plasma B-type natriuretic peptide (BNP) levels (before 3, and
 months later) and echocardiographic parameters (before and
 months later) were determined in each group. Patients were
ollowed up for cardiac events including cardiac death and re-
ospitalization due to worsening of heart failure after discharge.
olysomnography
All subjects underwent overnight polysomnography with the
se of standard techniques and scoring criteria for sleep stages
nd arousals from sleep as previously reported [9,10].  Brieﬂy,
vernight complete polysomnography was performed using a
omputerized system (Alice5, Philips Respironics, Murrysville, PA,
SA) that consisted of monitoring of the electro-encephalogram,
lectro-oculogram, submental electromyogram, electrocardio-
ram, thoracoabdominal motion, oronasal airﬂow by an airﬂow
ressure transducer, and arterial oxyhemoglobin saturation (SPO2)
y pulse oximetry [9,10].  Sleep-disordered breathing specialists
nalyzed the data. Apnea was deﬁned as an absence of inspira-
ion without ribcage and abdominal motion for more than 10 s.
ypopnea was deﬁned as a >30% reduction in monitored airﬂow
ccompanied by a decrease in SaO2 of >4% [9,10].  Arousal responses
ere deﬁned according to the recommendations of the American
leep Disorders Association. The AHI was deﬁned as the number of
pnea and hypopnea episodes per hour of sleep. A central apnea
as deﬁned as the absence of oronasal airﬂow for >10 s associated
ith an absent inspiratory effort. A CSR-CSA event was  considered
hen polysomnography revealed a waxing and waning pattern
f ventilation with an arousal at peak ventilation, followed by a
eriod of apnea with absence of respiratory effort [9,10].  Finally,
s
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SR-CSA was  deﬁned as AHI over 15 times/h, and a ratio of CSR-CSA
o total apnea events over 50% [8,9,19]. The major polysomno-
raphic parameters investigated were AHI, central apnea index
CAI), obstructive apnea index (OAI), minimal pulse oxygen satura-
ion (Min SPO2), 3% oxidative desaturation index (3% ODI), arousal
ndex, slow wave sleep (SWS), total sleep time (TST), rapid eye
ovement (REM) sleep/TST (%), %time < SPO2 90%/TST (CT90), and
time < SPO2 95%/TST (CT95) as previously reported [9,10].
chocardiography
Echocardiography was  performed using the standard tech-
iques as previously reported [9,10].  Two  dimensional echocar-
iographic images were acquired from the parasternal long and
hort axis, apical long axis, and apical four chamber views by an
xperienced echocardiographer who was blind to the patients’ clin-
cal data. We examined left ventricular end-diastolic volume index
LVEDVI), left ventricular end-systolic volume index (LVESVI), left
entricular ejection fraction (LVEF), left atrial volume index (LAVI),
stimated right ventricular systolic pressure (RVPS), and the ratio
f the peak transmitral velocity during early diastole to the peak
itral valve annular velocity during early diastole (E/E′). LVEDVI,
VESVI, and LVEF were calculated by a modiﬁcation of Simpson’s
ethod. The ratio of E/E′ was  calculated by transmitral Doppler
ow and tissue Doppler imaging. All recordings were performed
n the ultrasound system (Acuson Sequoia, Siemens, Erlangen,
ermany) [19].
easurement of plasma B-type natriuretic peptide level
Plasma BNP level was measured using a speciﬁc immunoradio-
etric assay (Shionoria BNP kit, Shionogi, Osaka, Japan) as reported
reviously [9,10].
etting of adaptive servo ventilation
We used two types of ASV (HEART PAP or BiPAP autoSV,
hilips Respironics) as reported previously [9,10].  Then, patients
nderwent a titration of the device overnight attended by
olysomnography. At the time of titration, we set expiratory pos-
tive airway pressure to eliminate obstructive apnea, and next set
ressure support and inspiratory positive airway pressure to elim-
nate CSR-CSA [9,10].
tatistical analysis
Data are presented as mean + SD, unless otherwise stated for
ontinuous variables. We  used the chi-square test for categori-
al variables and the independent t-test for continuous variables
etween two  groups. Levels of BNP are presented as medians (inter
uartile range) and analyzed by the Mann–Whitney U test and
ilcoxon signed-rank test. Event-free rate was analyzed by the
aplan–Meier method and compared by the log-rank test. A value
f p < 0.05 was  considered signiﬁcant for all comparisons. All analy-
es were performed using a statistical software package (StatView
ersion 5.0, SAS Institute Inc., Abacus Concepts, Berkeley, CA, USA).
esults
linical characteristics of study subjectsThe clinical characteristics of the ASV and non-ASV groups are
hown in Table 1. CRT responder was deﬁned as reduction of LVESVI
ore than 15% post CRT implantation over 6 months [11]. There
ere no differences in baseline clinical data such as age, gender,
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Table 1
Comparisons of clinical characteristics between ASV and Non-ASV groups.
ASV (n = 11) Non-ASV (n = 11) p-Value
Physical Age (years) 62.5 ± 8.0 61.5 ± 14.5 0.86
Male  (n, %) 10 (90.9) 10 (90.9) –
NYHA (I/IIs/IIm/III/IV) 0/0/4/7/0 0/0/4/6/1 0.58
Etiology Dilated cardiomyopathy (n, %) 8 (72.7) 7 (63.6) 0.65
Ischemic (n, %) 2 (18.2) 3 (27.3) 0.61
Congenital (n, %) 1 (9.1) 1 (9.1) –
CRT  responder 6 (54.5) 6 (54.5) –
Medication ACE  inhibitors (n, %) 8 (72.7) 7 (63.6) 0.65
ARBs (n, %) 2 (18.2) 2 (18.2) –
-Blockers (n, %) 11 (100) 11 (100) –
Diuretics (n, %) 11 (100) 11 (100) –
Aldosterone antagonist (n, %) 9 (81.8) 10(90.9) 0.53
Digitalis (n, %) 0 (0) 1 (9.1) –
Amiodarone (n, %) 9 (81.8) 8 (72.7) 0.61
Pimobendan (n, %) 4 (36.4) 3 (27.3) 0.65
Laboratory data BNP (pg/ml) 482.0 (530.1) 385.0 (349.0) 0.54
PaO2 (mmHg) 98.1 ± 16.6 90.8 ± 16.7 0.33
PaCO2 (mmHg) 37.2 ± 4.9 36.6 ± 2.5 0.75
Hb  (g/dl) 12.8 ± 2.0 12.1 ± 1.5 0.37
eGFR (ml/min/1.73 cm2) 59.3 ± 12.2 47.4 ± 19.0 0.21
ECG QRS pre CRT (ms) 144.1 ± 28.8 146.9 ± 25.0 0.86
QRS  post CRT (ms) 138.5 ± 21.1 140.5 ± 21.6 0.82
Af  (n, %) 6 (54.5) 5 (45.5) 0.82
ASV, adaptive servo ventilation; NYHA, New York Heart Association; CRT, cardiac resy
receptor blocker; BNP, B-type natriuretic peptide: median (inter quartile range); eGFR, es
Table  2
Baseline echocardiographic parameters.
ASV Non-ASV p-Value
LVEDVI (ml/m2) 114.8 ± 48.3 107.5 ± 45.9 0.72
LVESVI (ml/m2) 81.7 ± 42.2 78.2 ± 34.8 0.84
LVEF (%) 30.5 ± 13.9 30.2 ± 9.0 0.73
LAVI (ml/m2) 50.7 ± 21.0 61.6 ± 23.9 0.29
RVPS (mmHg) 38.1 ± 16.8 40.9 ± 11.7 0.67
E/E′ 16.5 ± 6.5 18.0 ± 11.0 0.70
ASV, adaptive servo ventilation; LVEDVI, left ventricular end-diastolic volume
index; LVESVI, left ventricular end-systolic volume index; LVEF, left ventricular ejec-
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/E′ , a ratio of the peak transmitral velocity during early diastole to the peak mitral
alve annular velocity during early diastole.
YHA functional status, etiologies of heart failure, CRT respon-
ers, medications, and laboratory data including plasma BNP levels
etween the ASV and non-ASV groups.
Baseline data of echocardiography are shown in Table 2. All
chocardiographic parameters including LVEDVI, LVESVI, LVEF,
AVI, RVPS, and E/E′ were similar between the ASV and non-ASV
roups.
Results of polysomnographic recordings at the time of enroll-
ent (baseline) are shown in Table 3. Baseline polysomnographic
ata were not signiﬁcantly different between the ASV and non-ASV
roups.
Changes in medication at baseline and 6 months later are as
ollows: In the ASV group, diuretics were reduced in 4 patients, and
ere increased in 2 patients. In the non-ASV group, diuretics were
educed in 1 patient, and were increased in 6 patients. Furthermore,
imobendan was added in 3 patients in the non-ASV group.
ffects of adaptive servo ventilation on polysomnographic dataIn the ASV group, all patients were successfully titrated on
SV. Changes in polysomnographic data at baseline and on ASV
n the ASV group are shown in Table 3. AHI (p < 0.01), CAI (p < 0.01),
p
K
n
(nchronization therapy; ACE, angiotensin-converting enzyme; ARB, angiotensin II
timated glomerular ﬁltration rate by the MDRD formula; ECG, electrocardiography.
rousal index (p < 0.01), 3%ODI (p < 0.01), lowest SPO2 (p < 0.01),
T90 (p = 0.02), and CT95 (p < 0.01), but not OAI, SWS, REM sleep,
nd sleep efﬁcacy, were signiﬁcantly improved on ASV.
After 6 months with ASV, compliance and efﬁcacy data were
ownloaded from the ASV device. The recorded average AHI was
.6 ± 2.0 times/h, mean device %usage of days was mean 82.3% of
ays, mean usage time was  324.5 min/day, and 4 h >usage (a ratio
f the use days more than 4 h) was 65.6%.
ffects of adaptive servo ventilation on cardiac function
In the ASV group, plasma BNP levels were signiﬁcantly
ecreased from baseline to 3 months [482 (530) pg/ml vs. 252
373) pg/ml, p < 0.05], and 6 months [482 (530) pg/ml vs. 221
217) pg/ml, p < 0.01] as shown in Fig. 1. However, plasma BNP lev-
ls were not changed from baseline to 6 months [385 (349) pg/ml
s. 388 (628) pg/ml, n.s.] in the non-ASV group.
The time course of cardiac function determined by echocardi-
graphy is shown in Table 4. LVESVI was  decreased and LVEF was
ncreased in both groups after 6 months. RVPS was decreased in
he ASV group (p = 0.04), but not in the non-ASV group. E/E′ was
igniﬁcantly improved in only the ASV group (p < 0.01).
omparisons of event-free rate between the ASV and non-ASV
roups
During the follow-up period (mean 349 days, range of 185–985
ays), there were 7 re-hospitalizations for worsening of heart
ailure. In the ASV and non-ASV groups, 1 patient and 6
atients were re-hospitalized, respectively. As shown in Fig. 2,
aplan–Meier analysis demonstrated that event-free rate was sig-
iﬁcantly higher in the ASV group than in the non-ASV group
p < 0.05).
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Table  3
Polysomnographic data at baseline and on ASV.
Baseline On-ASV p-Value
AHI (times/h) ASV
Non-ASV
39.0 ± 20.7
33.0 ± 17.8
5.9 ± 6.3 <0.01
CAI  (times/h) ASV
Non-ASV
14.8 ± 13.6
19.2 ± 19.3
0.6 ± 1.5 <0.01
OAI  (times/h) ASV
Non-ASV
1.3 ± 3.0
5.3 ± 7.1
0.5 ± 1.3 0.07
Arousal  index ASV
Non-ASV
21.9 ± 4.2
27.8 ± 13.9
13.6 ± 6.6 <0.01
3%  ODI (times/h) ASV
Non-ASV
30.5 ± 19.6
18.8 ± 15.8
3.3 ± 3.7 <0.01
Lowest  SPO2 (%) ASV
Non-ASV
77.3 ± 12.0
85.8 ± 7.3
87.8 ± 8.9 <0.01
CT90  (%) ASV
Non-ASV
20.4 ± 24.3
3.9 ± 5.1
1.9 ± 4.1 0.02
CT95  (%) ASV
Non-ASV
50.8 ± 40.3
17.4 ± 19.7
15.6 ± 27.6 <0.01
SWS  (%) ASV
Non-ASV
2.2 ± 2.0
2.1 ± 3.9
8.9 ± 13.7 0.12
REM  sleep (%) ASV
Non-ASV
22.1 ± 6.4
15.3 ± 5.2
16.9 ± 4.9 0.26
Sleep  efﬁcacy (%) ASV
Non-ASV
76.0 ± 10.6
61.3 ± 8.3
75.0 ± 11.5 0.93
ASV, adaptive servo ventilation; AHI, apnea-hypopnea index; CAI, central apnea index; OAI, obstructive apnea index; ODI, oxidative desaturation index; Lowest SPO2, lowest
oxyhemoglobin saturation; CT90, %time< SPO2 90%/total sleep time; CT95, %time< SPO2 95%/total sleep time; SWS, slow wave sleep; REM, rapid eye movement.
ASV No n-AS V
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(inter  quartile range)
Fig. 1. Changes in plasma B-type natriuretic peptide (BNP) levels: Comparisons between 
Levels  of BNP are presented as medians (inter quartile range) and analyzed by the Mann–
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Fig. 2. Kaplan–Meier analysis for all cardiac events between patients in adaptive
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Whitney U test and Wilcoxon signed-rank test.
iscussion
In the present study, the effects of ASV on CSR-CSA, cardiac func-
ion, and prognosis of CHF patients with CRT were examined. ASV
reatment during sleep reduced plasma BNP levels, RVPS, and E/E′
n CHF patients with CSR-CSA after CRT, suggesting that cardiac
verload and diastolic functions were ameliorated in CHF patients
ith CRT by ASV treatment. Furthermore, the event-free rate in the
SV group was  signiﬁcantly higher than that in the non-ASV group
n CHF patients post CRTD implantation.
RT to treat CSR-CSAEffective therapies for CHF such as optimal pharmacotherapy
ncluding ACE inhibitors and -blockers and CRT partially improve
he severity of CSR-CSA, but the effects of such therapies for CHF are
ot sufﬁcient to treat CSR-CSA [12–14].  Sinha et al. reported that
226 M. Miyata et al. / Journal of Card
Table 4
Changes in data of echocardiography after 6 months.
Baseline 6 months p-Value
LVEDVI (ml/m2)
ASV 114.8 ± 48.3 89.0 ± 48.6 0.06
Non-ASV 107.5 ± 45.9 87.6 ± 49.1 0.07
LVESVI (ml/m2)
ASV 81.7 ± 42.2 56.3 ± 36.1 0.04
Non-ASV 78.2 ± 34.7 62.1 ± 38.2 0.03
LVEF (%)
ASV 30.5 ± 13.9 36.0 ± 11.2 0.03
Non-ASV 30.2 ± 9.0 32.2 ± 8.8 0.02
LAVI (ml/m2)
ASV 50.7 ± 21.0 45.6 ± 17.1 0.39
Non-ASV 61.6 ± 23.9 56.7 ± 20.3 0.67
RVPS (mmHg)
ASV 38.1 ± 16.8 27.4 ± 18.4 0.04
Non-ASV 40.9 ± 11.7 40.0 ± 12.8 0.43
E/E′
ASV 16.5 ± 6.5 9.2 ± 4.1 <0.01
Non-ASV 18.0 ± 11.0 16.6 ± 9.3 0.35
ASV, adaptive servo ventilation; LVEDVI, left ventricular end-diastolic volume
index; LVESVI, left ventricular end-systolic volume index; LVEF, left ventricular ejec-
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Rion  fraction; LAVI, left atrial volume index; RVPS, right ventricular systolic pressure;
/E′ , a ratio of the peak transmitral velocity during early diastole to the peak mitral
alve annular velocity during early diastole.
RT improved CSA in CHF patients [12–14].  Their study subjects
ere CHF patients with mild to moderate CSA (average AHI 19.2/h)
efore CRT implantation. Although CRT led to a signiﬁcant decrease
n AHI from 19.2/h to 4.6/h (average) at 17 weeks after CRT, 4 out
f 14 patients still had AHI > 5/h after CRT. In addition, since CRT
andidates are associated with severely depressed left ventricular
unction and high rate of CSR-CSA, CSR-CSA is frequently observed
n CHF patients after CRT implantation. Furthermore, even though
hen patients are selected according to the aforementioned CRT
riteria, approximately 30% do not have a beneﬁcial response for
mproving heart failure [11]. In the present study, CRT respon-
ers were 54.5% and tended to be lower than usually reported
n both groups. Taken together, these data suggest that CSR-CSA
emains even after optimal medication and CRT implantation, and
peciﬁc therapy for CSR-CSA including ASV is required to treat such
atients. Therefore, we examined the effects of ASV on CSR-CSA,
ardiac function, and prognosis of CHF patients with CRT in the
resent study. We  demonstrated for the ﬁrst time, to the best of
ur knowledge that ASV improved cardiac function and clinical
utcomes in CHF patients after CRTD.
At 12 months after CRTD implantation, polysomnography was
erformed in the present study. All study subjects had stable clini-
al status, which was deﬁned as receiving optimal medical therapy
nd without worsening of CHF for at least 6 months prior to the
tudy enrollment. In the non-ASV group, although plasma BNP lev-
ls were unchanged, LVESVI was reduced and LVEF was  increased
fter 6 months. These changes might be explained by a long-term
eneﬁcial effect of CRT on cardiac function and ventricular reverse
emodeling [15].
SV for CSR-CSA in CHF
Recently, a randomized controlled prospective study in treating
HF and CSR-CSA has shown that ASV improves AHI and com-
liance (average usage time) more effectively than continuous
ositive airway pressure [16]. We  have recently shown that ASV
mproves cardiac systolic and diastolic function accompanied by reduction in left ventricular volume [16]. Our present data were
oncordant with a previous report by Oldenburg et al. showing that
SV improved LVEF (28.2–35.2%) [8].  ASV improves cardiac func-
ion regardless of sleep-disordered breathing severity and type.iology 60 (2012) 222–227
e  have also demonstrated that ASV improves the event-free rate
n patients with CHF and CSR-CSA [19]. In the present study, we
tudied 22 patients with AHI > 15/h at least 12 months after CRT
mplantation.
Several possible mechanisms for ASV to improve CHF and CSR-
SA have been suggested: (1) reduce the upper airway obstruction,
2) increase end-expiratory pulmonary volume and alveolar pres-
ure, (3) assist inspiratory muscles [16], (4) reduce cardiac pre
nd after load [17], (5) decrease left ventricular volume [18,19],
6) attenuate sympathetic nervous activity resulting in the sup-
ression of lethal arrhythmias, and (7) anti-inﬂammatory effect
20]. In the present study, ASV might have improved CSR-CSA, car-
iac function, and event-free survival of CHF patients with CRT by
hese mechanisms. In particular, attenuation of sympathetic ner-
ous activity might lead to decreasing the rate of re-hospitalization
ue to worsening of CHF. ASV should be used to treat CSR-CSA in
HF patients with CRT.
tudy limitations
The numbers of study subjects were small, since this study was
erformed in a single institution. Patients were randomly assigned
nto two  groups in the present study. Clinical background, labo-
atory, and echocardiographic data were similar between the two
roups. Polysomnographic data tended to be somewhat worse in
he ASV group compared to the non-ASV group, although these
ere not statistically signiﬁcant. In this study, since we examined
HF patients more than 12 months after CRTD implantation, we
annot completely deny the inﬂuence of CRT. Further studies with
 larger population are necessary to establish ASV as a promising
herapy for CHF with CRT.
onclusions
ASV improves CSR-CSA, cardiac systolic and diastolic function,
nd event-free survival in CHF patients with CRT. After CRTD
mplantation, CHF patients with CSR-CSA are at increased risk of
e-hospitalization and may  warrant additional therapy with ASV.
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